(RTTNews) - AstraZeneca (AZN) said Tuesday that full results from the Phase 3 CROSSING trial showed Tezspire improved disease remission and swallowing symptoms in adolescents and adults with eosinophilic esophagitis.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.